It depends on who's perspective you're referring t
Post# of 148154
Quote:
Why not release the section of the FDA Guidance which concerns the Clinical Section dealing with the dose justification? Then, shareholders can make their own judgement as to how addressable they are and skeptics will be silenced if the FDA wording is consistent with Nader's PR statement.